Welcome to our dedicated page for Macrogenics SEC filings (Ticker: MGNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech reports can feel like a second language鈥攅specially when MacroGenics鈥� 10-K stretches across hundreds of pages of antibody platform science, trial data, and partnership milestones. If you have ever searched Google for 鈥淢acroGenics SEC filings explained simply鈥� or wondered where to track 鈥淢acroGenics insider trading Form 4 transactions,鈥� you know the challenge.
Stock Titan solves that problem. Our AI instantly translates every new document鈥攚hether it鈥檚 a 鈥淢acroGenics quarterly earnings report 10-Q filing,鈥� an 8-K on fresh trial results, or a detailed proxy statement on executive compensation鈥攊nto plain-English summaries with key numbers highlighted. AG真人官方-time alerts surface 鈥淢acroGenics Form 4 insider transactions鈥� the moment executives buy or sell shares, while side-by-side visuals compare R&D spend trends across quarters. No more combing through dense exhibits to find collaboration revenue or cash-runway disclosures.
Inside this page you鈥檒l find comprehensive coverage of every submission to EDGAR, including:
- 10-K / Annual Report: Cash burn, pipeline status, and 鈥淢acroGenics annual report 10-K simplified鈥� sections for instant context.
- 10-Q / Earnings: 鈥淢acroGenics earnings report filing analysis鈥� that links trial costs to balance-sheet strength.
- 8-K Material Events: 鈥淢acroGenics 8-K material events explained,鈥� from FDA designations to partnership amendments.
- Form 4: 鈥淢acroGenics executive stock transactions Form 4鈥� with real-time AI tagging.
- DEF 14A Proxy: Clear breakdowns of 鈥淢acroGenics proxy statement executive compensation.鈥�
Whether you鈥檙e monitoring catalyst dates or simply understanding MacroGenics SEC documents with AI, Stock Titan delivers the insights professionals rely on鈥攆aster, clearer, and always up to date.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 5,960,000 shares of MacroGenics, Inc. (MGNX), equal to 9.45% of the outstanding common stock based on 63,090,323 shares outstanding as of May 9, 2025. The filing discloses that Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd. (the Master Fund), and Mr. Boyd, as managing member of Armistice Capital, each have shared voting and shared dispositive power over these shares and hold no sole voting or dispositive power. The Master Fund is the direct holder and retains the right to receive dividends or sale proceeds. This is an amendment (No. 5) to the Schedule 13G filed with the SEC.
The Frazier Life Sciences reporting group disclosed specific holdings in MacroGenics common stock. Frazier Life Sciences Public Fund, L.P. directly holds 1,549,193 shares representing 2.5% of the 63,090,323 shares outstanding used for the percentage calculation. Other reporting entities hold 925,809 shares (1.5%), 575,150 shares (0.9%) and 125,513 shares (0.2%).
The filing states that voting and dispositive power for these shares is shared rather than sole and corrects prior attributions by clarifying that members of certain investment committees are not attributed beneficial ownership of the securities held by the respective funds. The statement also notes the reporters do not admit broader beneficial ownership or group status beyond what is disclosed.
MacroGenics appointed Eric Risser as President, Chief Executive Officer and elected him as a Class I director with a term expiring at the 2026 annual meeting. Mr. Risser, previously the company鈥檚 Chief Operating Officer, became the company鈥檚 principal executive officer effective August 13, 2025.
The company agreed an amended employment arrangement providing a $625,000 annual base salary, eligibility for annual incentive pay up to 60% of base salary, and a stock option to purchase 550,000 shares at the closing price on the effective date. Termination protections include cash severance (typically 1.0x salary plus 1.0x target bonus prorated, increased to 1.5x for change-of-control scenarios), COBRA premium coverage up to 18 months, and acceleration of unvested equity upon certain change-of-control terminations.
On 07/07/2025, Bellevue Group AG and its wholly-owned subsidiary, Bellevue Asset Management AG, filed a Schedule 13G revealing a 9,929,963-share position in MacroGenics, Inc. (MGNX) as of 06/01/2025. The stake equals 15.7 % of the company鈥檚 outstanding common stock. Both entities are incorporated in Switzerland and report shared voting and dispositive power over the entire holding, with zero sole voting or dispositive authority. Bellevue is classified as a 鈥淗C, CO鈥� (parent holding company/control person) and Bellevue Asset Management AG as 鈥淐O.鈥�
The certification states that the shares were acquired and are held in the ordinary course of business and are not intended to influence control of MacroGenics. This filing increases transparency around MacroGenics鈥� ownership structure and highlights a sizeable passive investment from a regulated Swiss financial institution.
FAQ
What is the current stock price of Macrogenics (MGNX)?
What is the market cap of Macrogenics (MGNX)?
